HealthLinx: OvPlex Ovarian Cancer Diagnostic Patented in UK
HealthLinx managing director Mr Nick Gatsios said the UK patent represents an important validation of the OvPlex™ panel’s first in class technology. “This is a major milestone for the company to have our core patent granted in a major jurisdiction such as the UK,” he said.
The OvPlex™ test examines a series of biomarkers from a blood sample deemed important in the diagnosis of ovarian cancer. It includes the current ‘gold standard’ biomarker CA125. Importantly, the granted patent covers not only the combination of proprietary biomarkers, but also the methodology used for implementing the test in a typical clinical pathology environment.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.